NOVARTIS-EGF104900



A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination with Trastuzumab versus Lapatinib Monotherapy in Subjects with HER2-positive Metastatic Breast Cancer whose disease has progressed on Trastuzumab-Containing Regimens
lapatinib
EGF104900
NCT00320385
Neoplasms, Breast
Phase 3
 
The raw dataset is included within the analysis-ready dataset.
June 2014